IDEXX LABORATORIES INC /DE — Director's Dealing 2021

Nov 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2021-11-10

Reporting Person: MCKEON BRIAN P (Executive VP & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-10	Common Stock	M	20000	$67.85	Acquired	46316.6426	Direct
2021-11-10	Common Stock	S	1262	$621.3970	Disposed	45054.6426	Direct
2021-11-10	Common Stock	S	5743	$622.3637	Disposed	39311.6426	Direct
2021-11-10	Common Stock	S	1493	$623.3416	Disposed	37818.6426	Direct
2021-11-10	Common Stock	S	2142	$624.5318	Disposed	35676.6426	Direct
2021-11-10	Common Stock	S	2326	$625.4647	Disposed	33350.6426	Direct
2021-11-10	Common Stock	S	1813	$626.7411	Disposed	31537.6426	Direct
2021-11-10	Common Stock	S	2974	$627.9664	Disposed	28563.6426	Direct
2021-11-10	Common Stock	S	1375	$628.7812	Disposed	27188.6426	Direct
2021-11-10	Common Stock	S	872	$629.8004	Disposed	26316.6426	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-10	Non-Qualified Stock Option (right-to-buy)	$67.85	M	20000	Disposed	2026-02-13	Common Stock (20000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	18050	Indirect

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $620.78 to $621.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: This transaction was executed in multiple trades at prices ranging from $621.79 to $622.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $622.97 to $623.965. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $624.04 to $625.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $625.06 to $626.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6: This transaction was executed in multiple trades at prices ranging from $626.10 to $627.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F7: This transaction was executed in multiple trades at prices ranging from $627.32 to $628.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F8: This transaction was executed in multiple trades at prices ranging from $628.34.10 to $629.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F9: This transaction was executed in multiple trades at prices ranging from $629.46 to $630.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F10: Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017.

F11: Not applicable.